Deciphering the MHC-associated peptidome: a review of naturally processed ligand data

Expert Review of Proteomics

Volumn 14, Issue 9, 2017, Pages 729-736

  Vaughan, Kerrie ^a   Xu, Xiaojun ^a   Caron, Etienne ^b   Peters, Bjoern ^a   Sette, Alessandro ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b Institute of Molecular Systems Biology   (Switzerland)

Author keywords

Epitopes; HLA; ligand; ligandome; mass spectrometry; MHC; naturally processed; peptidome; T cell

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MINOR HISTOCOMPATIBILITY ANTIGEN; NATURALLY PROCESSED PEPTIDE; PEPTIDE; UNCLASSIFIED DRUG; AUTOANTIGEN; LIGAND; PROTEIN BINDING;

ARTICLE; HUMAN; IMMUNOBIOLOGY; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; NONHUMAN; REFERENCE DATABASE; T LYMPHOCYTE; AMINO ACID SEQUENCE; GENE; GENETICS; IMMUNOLOGY; PROCEDURES;

AMINO ACID SEQUENCE; AUTOANTIGENS; EPITOPES, T-LYMPHOCYTE; GENES, MHC CLASS I; HUMANS; LIGANDS; MASS SPECTROMETRY; PEPTIDES; PROTEIN BINDING;

EID: 85027312567     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1080/14789450.2017.1361825     Document Type: Article

References (25)

1. Istrail S, Florea L, Halldórsson BV, et al. Comparative immunopeptidomics of humans and their pathogens. Proc Natl Acad Sci USA. 2004;101:13268–13272.
2. Purcell AW, McCluskey J, Rossjohn J., More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov. 2007;6:404–414.
3. Koff WC, Burton DR, Johnson PR, et al. Accelerating next-generation vaccine development for global disease prevention. Science. 2013;340:1232910.
4. Hassan C, Kester MG, de Ru AH, et al. The human leukocyte antigen-presented ligandome of B lymphocytes. Mol Cell Proteomics. 2013;12:1829–1843.•• This is a key reference showing how naturally processed peptides might be selectively generated from particular off/expression patterns.
5. Pearson H, Daouda T, Granados DP, et al. MHC class I-associated peptides derive from selective regions of the human genome. J Clin Invest. 2016;126:4690–4701.
6. Bassani-Sternberg M, Bräunlein E, Klar R, et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun. 2016;7:13404.• This paper represents a classic example of characterization of naturally processed peptides.
7. Caron E, Kowalewski DJ, Koh CC, et al. Analysis of MHC immunopeptidomes using mass spectrometry. Mol Cell Proteomics. 2015;14:3105–3117.• This paper represents a classic example of characterization of naturally processed peptides.
8. Bassani-Sternberg M, Barnea E, Beer I, et al. Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proc Natl Acad Sci USA. 2010;107:18769–18776.• This paper represents a classic example of characterization of naturally processed peptides.
9. Van Bleek GM, Nathenson SG., Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature. 1990;348:213–216.• This paper represents an early example of isolation of natural ligands.
10. Rötzschke O, Falk K, Deres K, et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature. 1990;348:252–254.• This paper represents an early example of isolation of natural ligands.
11. Rötzschke O, Falk K, Wallny HJ, et al. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science. 1990;249:283–287.• This paper represents an early example of isolation of natural ligands.
12. Falk K, Rötzschke O, Rammensee HG. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature. 1990;348:248–251.• This paper represents an early example of isolation of natural ligands.
13. Storkus WJ, Zeh HJ, 3rd, Salter RD, et al. Identification of T-cell epitopes:rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother Emphasis Tumor Immunol. 1993;14:94–103.
14. Peters B, Sidney J, Bourne P, et al. The immune epitope database and analysis resource:from vision to blueprint. PLoS Biol. 2005;3:e91.
15. Vita R, Overton JA, Greenbaum JA, et al. The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 2015;43:D405–12.
16. Mutschlechner S, Egger M, Briza P, et al. Naturally processed T cell-activating peptides of the major birch pollen allergen. J Allergy Clin Immunol. 2010;125:711–718.
17. Van Overtvelt L, Wambre E, Maillère B, et al. Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers. J Immunol. 2008;180:4514–4522.
18. Falk K, Rötzschke O, Stevanović S, et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991;351:290–296.
19. Kotturi MF, Scott I, Wolfe T, et al. Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J Immunol. 2008;181:2124–2133.• This paper is an important reference describing immunodominance.
20. Yewdell JW. Confronting complexity:real-world immunodominance in antiviral CD8+ T cell responses. Immunity. 2006;25:533–543.• This paper is an important reference describing immunodominance.
21. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol. 1999;17:51–88.
22. Fleri W, Vaughan K, Salimi N, et al. The immune epitope database:how data are entered and retrieved. J Immunol Res. 2017;2017:5974574.•• This is an up-to-date reference describing IEDB usage and functionality.
23. Fleri W, Paul S, Dhanda SK, et al. The immune epitope database and analysis resource in epitope discovery and synthetic vaccine design. Front Immunol. 2017;8:278.•• This is an up-to-date reference describing IEDB usage and functionality.
24. Desiere F, Deutsch EW, King NL, et al. The PeptideAtlas project. Nucleic Acids Res. 2006 Jan;1(34):D655–8.
25. Nesvizhskii AI, Aebersold R. Analysis, statistical validation and dissemination of large-scale proteomics datasets generated by tandem MS. Drug Discov Today. 2004;9:173–181.